Table 1.
Baseline clinical characteristics
| GH group (n = 15) | Placebo group (n = 15) | |
|---|---|---|
| Male/female | 6/9 | 7/8 |
| History of surgery | 13 | 14 |
| History of radiation therapy | 12 | 11 |
| Time since acromegaly diagnosis (months) | 136.4 ± 100.1 | 177.6 ± 141.1 |
| Time since cure (months) | 67.6 ± 58.6 | 109.4 ± 115.6 |
| Hypoadrenal | 7 | 7 |
| Hypothyroid | 10 | 12 |
| Hypogonadal (male) | 4 | 6 |
| Testosterone use | 4 | 6 |
| Hypogonadal (female) | 7 | 6 |
| Oral estrogen use | 4 | 4 |
| Transdermal estrogen use | 1 | 1 |
| Current tobacco use | 2 | 2 |
| Age (yr) | 46.1 ± 13.1 | 47.5 ± 11.4 |
| BMI (kg/m2) | 30.9 ± 6.1 | 31.8 ± 7.0 |
| Weight (kg) | 90.0 ± 19.0 | 92.5 ± 25.6 |
| IGF-I (ng/ml) | 92.9 ± 38.9 | 93.1 ± 58.7 |
| IGF-I SDS | −1.98 ± 0.60 | −1.99 ± 0.74 |
| Free T4 (ng/dl) | 1.15 ± 0.39 | 1.14 ± 0.23 |
Values are reported as mean ± sd. Free T4 normal range is 0.9–1.8 ng/dl; there was no significant difference between the groups in any parameter.